Pos: 53 /Ar bei tsanl eitungen ELISA cl assic/Gültig für all e D okumente/ELISA classic/Liter atur/Kapitelüberschrift: Liter atur @ 0\mod_1190013903728_18.doc @ 9956 @ 110 SAFETY MEASURESEN10.1 Statements of WarningThe SERION ELISA classic is designed for use by qualified personnel who are familiarwith good laboratory practice.EL ENAll kit reagents and human specimens should be handled carefully, using established goodlaboratory practice.- This kit contains human blood components. Although all control- and cut-off serahave been tested and found negative for anti-HIV-ab, HBs-Ag (Hepatitis B-VirussurfaceAntigen) and anti-HCV-ab, they should be considered potentially infectious.- Do not pipette by mouth.- Do not smoke, eat or drink in areas in which specimens or kit reagents are handled.- Wear disposable gloves, laboratory coat and safety glasses while handling kitreagents or specimens. Wash hands thoroughly afterwards.- Patient’s material and other potentially infectious material should bedecontaminated after the test run.- Reagents should be stored safely and be unaccessible to unauthorized access e.g.children.- Stopping solution: corrosive (C); causes acid burn (R34)Use safety glasses, gloves and laboratory coat while handling!CS PT10.2 DisposalPlease observe the relevant statutory requirements!english 23
=== Ende der Liste für T extmar ke Inhalt ===11 REFERENCESPos: 54 /Ar bei tsanl eitungen ELISA cl assic/Gültig für nur ein D okument/Literatur /<strong>Influenza</strong>: Liter atur @ 11\mod_1329739752063_0.doc @ 50503 @[1] Beyer, W.E.P., van der Logt, J.T.M., van Beek R., Masurel, N. (1986)Immunglobulin G,A and M response to influenza Vaccination in different agegroups: effects of priming and boosting. J. Hyg. Camb. 96, 513-22.[2] Cox, R.J. & Brokstad, K.A. (1999) The postvaccination antibody response toinfluenza virus proteins. APMIS. 107, 289-96.[3] Cox, R. J., Brokstad, K. A., Ogra, P. (2004) <strong>Influenza</strong> Virus: immunity andvaccination strategies. Comparison of the immune response to inactivated and liveattenuated<strong>Influenza</strong> vaccines. Scan. J. Immunol. 59, 1-15.[4] Döller, G., Gerth, H. J. (1991) Evaluierung der Einzelserumdiagnose nach<strong>Influenza</strong>-Infektionen. Lab. med. 15, 560-2.[5] Mertens, T., Haller, O., Klenk, H.-D. (2004) Diagnostik und Therapie von Viruskrankheiten.Elsevier, 2. Auflage.[6] Robert Koch Institut (1999) Aktuelle Daten und Informationen zu Infektionskrankheiten:<strong>Influenza</strong>virus-Infektionen (Virusgrippe). Epidemiologisches Bulletin 7.[7] Rothbarth, P. H., Groen, J., Bohnen, A. M., de Groot, R., Osterhaus, A.D.M.E.(1999) <strong>Influenza</strong> virus serology - a comparative study. J. Virol. Meth. 78, 163-9.[8] Shaw, M. W., Arden, N. H., Maassab, H. F. (1992) New Aspects of <strong>Influenza</strong>Viruses. Clin. Microbiol. Rev. 5, 74-92.[9] Vikerfors, T. Lindegren, G. Grandien, M. van der Logt, J. (1989) Diagnosis of<strong>Influenza</strong> A Virus infection by detection of specific immunglobulins M, A, and G inSerum. J. Clin. Microbiol. 27:3, 453-458.[10] Voeten, J.T., Groen, J., van Alphen, D., Claas, E.C., de Groot, R., Osterhaus, A.D.,Rimmelzwaan, G.F. (1998) Use of recombinant nucleoproteins in enzyme-linkedimmunosorbent assays for detection of virus-specific immunoglobulin A (IgA) andIgG antibodies in influenza virus A- or B-infected patients. J. Clin. Microbiol. 36,3527-31.english 24